The Rise of Indigenous Dengue Fever Cases in Iran: An In-Depth Examination of the Initial Significant Outbreak in Sistan and Baluchestan Province, 2024 - Takeaways - MDSpire

The Rise of Indigenous Dengue Fever Cases in Iran: An In-Depth Examination of the Initial Significant Outbreak in Sistan and Baluchestan Province, 2024

  • By

  • Madineh Abbasi

  • Ehsan Sheykh Noori

  • Faramarz Mobaraki

  • Omid Dehghan

  • Fatemeh Nikpour

  • Ahmad Raeisi

  • Abdolreza Mirolyaie

  • Mahasti Alizadeh

  • Ahmad Koosha

  • Saideh Yousefi

  • February 6, 2026

  • 0 min

Share

  • 1

    Dengue fever is a significant arboviral disease transmitted by Aedes mosquitoes, with four serotypes and no universally approved treatment or vaccine.

  • 2

    The Eastern Mediterranean Region has seen a rise in dengue cases, with Iran facing increased risk due to established Aedes mosquito populations and regional connectivity.

  • 3

    In 2024, Iran confirmed its first autochthonous dengue transmission, marking a shift from previously reported imported cases.

  • 4

    The outbreak in Sistan and Baluchestan Province was catalyzed by the establishment of Aedes aegypti in Chabahar, enabling local transmission.

  • 5

    Epidemiological studies are essential for understanding dengue dynamics in Iran and informing public health strategies for prevention and management.

Original Source(s)

The Rise of Indigenous Dengue Fever Cases in Iran: An In-Depth Examination of the Initial Significant Outbreak in Sistan and Baluchestan Province, 2024

  • by Madineh Abbasi, Ehsan Sheykh Noori, Faramarz Mobaraki, Omid Dehghan, Fatemeh Nikpour, Ahmad Raeisi, Abdolreza Mirolyaie, Mahasti Alizadeh, Ahmad Koosha, Saideh Yousefi

  • February 6, 2026

Related Content

A new Ebola outbreak is confirmed in a remote Congo province, with 65 deaths recorded

Varicella Pneumonia Requires IV Acyclovir

Case highlights need for early intravenous antiviral treatment in adults with rash and hypoxia

RSV Prevention Tied to Lower Infant Acute Care Use

Data suggest fewer respiratory syncytial virus–associated hospitalizations and emergency department visits among the youngest infants during the second season of routine prevention product use.